Yet another gaming of the inherent inadequacy of vaccinations is sure to result in ever more of the autoimmune disorders plaguing modern society. New research is focused on a bioengineered nanoparticle adjuvant that’s copies a normal part of the autoimmune system.
Published in the journal Nature, “Synthetic mast-cell granules as adjuvants to promote and polarize immunity in lymph nodes” discusses the use of a new adjuvant that contains an inflammation booster called tumor necrosis factor (TNF, sometimes notated as TNF-α), which triggers inflammation. These particles can travel to the lymph nodes and initiate the development of antibodies. Interestingly, the researchers do not claim to prevent infections by using TNF as an adjuvant. Instead, they say that the mice used in trials were better able to fight infections.
The researchers had observed that mast cells, immune system cells found in the skin, use nano-sized granules to communicate with lymph nodes for the production of antibodies. So, they set out to duplicate the process. As researcher Ashley L. St. John stated:
Our strategy is unique because we have based our bioengineered particles on those naturally produced by mast cells, which effectively solve the same problem we are trying to solve of combating infection.
These bioengineered particles consist of a carbohydrate bound to TNF. Apparently, they can carry or drag the antigen injected with them to a lymph node, where antibodies are made. This biologically active adjuvant results in a much stronger immune response than that triggered by other adjuvants.
What the authors don’t consider is whether these engineered bits of encapsulated TNF might also drag things other than the intended antigen to lymph nodes, thus creating even worse autoimmune diseases than already occurring as the result of existing vaccine adjuvants. There’s no indication that the researchers have any intention of investigating the possibility.
Vaccines using this adjuvant are expected soon, because the FDA has already approved all the ingredients and all the immune system factors used in the adjuvant. In all likelihood, no testing will be required. Once an ingredient is approved for one use, it’s assumed safe for virtually any use—including injections.
Autoimmune disorders are the result of an immune system that’s gone on overdrive. It sees normal tissues as foreign, so attempts to destroy them. Rheumatoid arthritis is a prime example, as it’s a result of the body attacking its own connective tissue, collagen. Several disorders have been linked to vaccine adjuvants, including arthritis, type 1 diabetes mellitus, multiple sclerosis, lupus erythematosus, macrophagic myofasciitis, chronic fatigue syndrome, Gulf War syndrome, and autism. (See “Mechanisms of Aluminum Adjuvant Revealed: Vaccine Risks to Children Clarified“.)
The researchers noted that Th1 lymphocytes (one of two T-cells that are the focus of AIDS blood tests) are activated. As Tomljenovic and Shaw noted in “Mechanisms …“, excessive Th1 is associated with many autoimmune disorders, including arthritis, autoimmune thyroid disease, inflammatory bowel disease, type 1 diabetes mellitus, Gulf War Syndrome, and autism.
Further, increased TNF, the adjuvant itself, is associated with several autoimmune disorders, including arthritis, type 1 diabetes mellitus, multiple sclerosis, systemic lupus erythematosus, and autism. Using TNF as an adjuvant is clearly playing with autoimmune fire.
Another concern with the use of TNF as an adjuvant is its potential to trigger allergic reactions. The study states that mast cells are “enhanced” by the TNF adjuvant. Mast cells are found in connective tissue throughout the body, including the skin, mucus membranes, joints, and stabilizing tissues that hold organs in place. They are noted for their involvement in allergic reactions, including anaphylactic shock.
Mast cells trigger allergic reactions, such as itching, hives, and anaphylactic shock. What effect can their “enhancement” have on allergies? We don’t know—and the researchers don’t appear to be interested in investigating. We should assume that using TNF as an adjuvant is playing with allergy fire.
There is no testing of TNF adjuvant planned in humans. As previously noted, the FDA has already approved all the ingredients. Therefore, the FDA will likely give its approval without any requirement for testing on humans. That shouldn’t be too surprising, since no previous adjuvant has undergone testing, either.
Do these risks worry the medical profession? As a rule, they do not. And why should they? They’re good for business. New medical businesses are created with each health incursion by existing medical procedures. For example, Allecure is a company that’s focused on developing treatments for immune system disorders. Pharmaceuticals of all sorts are prescribed massively to treat every disease named above.
Unless people go outside the mainstream medical system, not one of these diseases is curable, and all of them severely degrade both the quality of life and longevity. But as long as profitable treatments exist within conventional medicine, there’s little or no motivation to find cures—and obviously none to actually prevent autoimmune diseases and allergies.
In all likelihood, TNF adjuvants will soon be added to vaccines—and we’ll be off on a new era of vaccine damage. Who knows? Maybe autism will become the new normal. Perhaps we’ll start seeing antihistamines put in the water system to counter allergic reactions.
The one thing we aren’t likely to see any time soon is an application of the Precautionary Principle. There simply isn’t any profit in it.
Tagged adjuvant, big pharma, big pharma profits, conventional medicine, fda, fda adjuvant, fda adjuvant testing, mast cells vaccines, medicine profits, pharmaceutical drugs, pharmaceuticals, tnf adjuvant, tnf adjuvant study, tnf vaccine adjuvant, tnf vaccines, tumor necrosis factor, tumor necrosis factor adjuvant, vaccine, vaccines